LOX-IN-3 dihydrochloride monohydrate

Modify Date: 2024-01-12 21:16:59

LOX-IN-3 dihydrochloride monohydrate structure	Common Name	LOX-IN-3 dihydrochloride monohydrate
	CAS Number	2414974-55-1	Molecular Weight	371.26
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₃H₁₇Cl₂FN₂O₃S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of LOX-IN-3 dihydrochloride monohydrate

LOX-IN-3 dihydrochloride monohydrate (Compound 33) is an orally active lysyl oxidase (LOX) inhibitor. LOX-IN-3 dihydrochloride monohydrate can be used for fibrosis, cancer and angiogenesis research[1].

Name	LOX-IN-3 dihydrochloride monohydrate

Description	LOX-IN-3 dihydrochloride monohydrate (Compound 33) is an orally active lysyl oxidase (LOX) inhibitor. LOX-IN-3 dihydrochloride monohydrate can be used for fibrosis, cancer and angiogenesis research[1].
Related Catalog	Research Areas >> Cancer Research Areas >> Cardiovascular Disease Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase
Target	IC50: <1 μM (human LOXL2), <10 μM (bovine LOX)[1]
In Vitro	LOX-IN-3 dihydrochloride monohydrate (Compound 33) inhibits the bovine LOX and human LOXL2 activities with IC50 values of <10 μM and <1 μM, respectively[1]. LOX-IN-3 dihydrochloride monohydrate exhibits sustained inhibition of LOXL1 and LOXL2[1]. LOX-IN-3 dihydrochloride monohydrate is less active against SSAO/VAP-1 and MAO-B activities[1].
In Vivo	LOX-IN-3 dihydrochloride monohydrate (Compound 33) (30 mg/kg; orally; once) inhibits lysyl oxidase activity in rats[1]. LOX-IN-3 dihydrochloride monohydrate (10 mg/kg; orally; daily for 14 days) reduces kidney fibrosis in unilateral ureteric obstruction (UUO) mice model[1]. LOX-IN-3 dihydrochloride monohydrate (15 mg/kg; orally; daily for 21 days) reduces lung fibrosis in mice[1]. Animal Model: Male Wistar rats[1] Dosage: 30 mg/kg Administration: Oral administration, single dose Result: Completely abolished lysyl oxidase activity. Plasma concentrations of tested compound are far below the IC50 after 8 hours, the half-life of recovery is between 2-3 days (ear) and 24 hours (aorta). Animal Model: Unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in mice[1] Dosage: 10 mg/kg Administration: Oral gavage, daily for 14 days Result: Increased kidney weight and thickness and reduced the area of fibrosis. Animal Model: C57Bl/6 mice, Bleomycin-induced lung fibrosis model Dosage: 15 mg/kg Administration: Oral gavage, daily for 21 days Result: Significantly reduced the Ashcroft score and the lung weight.
References	[1]. Alison Dorothy Findlay, et al. Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof. WO2020024017A1.

Molecular Formula	C₁₃H₁₇Cl₂FN₂O₃S
Molecular Weight	371.26